- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NeuroOne erhält 200.000 USD aus NIH-Forschungszuschuss für Neurotransmitter-Technologie | 1 | Investing.com Deutsch | ||
| Mo | NeuroOne: Vorläufiger Q4-Umsatz steigt auf 3,8 Millionen US-Dollar | 3 | Investing.com Deutsch | ||
| Mo | NeuroOne Medical Technologies Corporation: NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order | 152 | GlobeNewswire (Europe) | Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| Mo | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 10.09. | NeuroOne auf der Moody Capital Konferenz: Dünnschicht-Plattform soll Wachstum vorantreiben | - | Investing.com Deutsch | ||
| 27.08. | EQS-News: NeuroOne Medical Technologies: NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED Platform | 539 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED Platform 27.08.2026... ► Artikel lesen | |
| 27.08. | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | 2 | SEC Filings | ||
| NEUROONE MEDICAL TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.08. | NeuroOne: Product Revenue Jumps 105% As Gross Margin Expands Nearly 20 Percentage Points In Fiscal Q3 2025 | 1 | pulse2.com | ||
| 13.08. | NeuroOne expects FY2026 product orders of about $11.2M while working to clear backlog by Q4 2026 | 2 | Seeking Alpha | ||
| 13.08. | Earnings Call: NeuroOne Medical steigert Umsatz im dritten Quartal, Aktie gibt dennoch nach | 2 | Investing.com Deutsch | ||
| 13.08. | NeuroOne Medical Technologies GAAP EPS of -$0.28 misses by $0.06, revenue of $2M misses by $0.55M | 1 | Seeking Alpha | ||
| 13.08. | NEUROONE MEDICAL TECHNOLOGIES Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.08. | NEUROONE MEDICAL TECHNOLOGIES Corp - 8-K, Current Report | - | SEC Filings | ||
| 13.08. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% | 1.400 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins... ► Artikel lesen | |
| 11.08. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification | 1.529 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification 11.08.2026 / 14:35 CET/CEST
The issuer is... ► Artikel lesen | |
| 03.08. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time | 350 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m.... ► Artikel lesen | |
| 30.07. | EQS-News: NeuroOne Medical Technologies: NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED Platform | 516 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Science
NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED Platform... ► Artikel lesen | |
| 28.07. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians | 450 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based... ► Artikel lesen | |
| 16.07. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial | 479 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial 16.07.2026... ► Artikel lesen | |
| 29.06. | EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Added to Russell Microcap(R) Index | 414 | EQS Group (EN) | EQS-News: NeuroOne Medical Technologies
/ Key word(s): Financial
NeuroOne(R) Added to Russell Microcap(R) Index 29.06.2026 / 14:35 CET/CEST
The issuer is solely responsible... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADAPTHEALTH | 6,065 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,65 | 0,00 % | BMO Capital reiterates Outperform on BrightSpring Health stock | ||
| ALIGNMENT HEALTHCARE | 8,720 | +0,11 % | Alignment Healthcare earns 4-Star or higher ratings for six plans | ||
| HEARTFLOW | 47,590 | -0,08 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BILLIONTOONE | 95,41 | 0,00 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| PROGYNY | 27,820 | -0,04 % | Progyny expects 1.2 million new covered lives in 2027 | ||
| AVEANNA HEALTHCARE | 12,235 | -0,04 % | Aveanna Healthcare Holdings, Inc. - 8-K, Current Report | ||
| PRIVIA HEALTH GROUP | 20,180 | -0,05 % | Privia Health Group, Inc.: Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 | ||
| GENEDX | 67,67 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| LIFESTANCE HEALTH GROUP | 12,060 | 0,00 % | Transcript: LifeStance Health Gr Q2 2026 Earnings Conference Call | ||
| BETA BIONICS | 17,440 | +0,06 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| FRESENIUS | 42,280 | +1,66 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius vor einem Treffen mit dem Chef Michael Sen auf "Buy" mit einem Kursziel von 55 Euro belassen. Die geschäftliche... ► Artikel lesen | |
| CONCENTRA GROUP | 36,670 | 0,00 % | Why Concentra's Quiet Healthcare Business Keeps Winning | ||
| FRESENIUS MEDICAL CARE | 37,470 | +2,04 % | Fresenius Medical Care: Plötzlicher Führungswechsel schürt Zweifel an Zukunft - Kurs bricht weiter ein | Der überraschende Führungswechsel bei Fresenius Medical Care lässt die Aktie abstürzen und schürt Spekulationen über einen radikalen Kurswechsel im angeschlagenen Dialysegeschäft. Anleger und Analysten... ► Artikel lesen | |
| NEUROPACE | 12,390 | 0,00 % | KeyBanc initiates NeuroPace stock coverage with overweight rating |
Das Unternehmen NEUROONE MEDICAL TECHNOLOGIES CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROONE MEDICAL TECHNOLOGIES CORPORATION finden Sie auf Wallstreet Online.